Q1 results from Eris Lifesciences. Prima facie, results look mixed.
However, company has guided for 30 pc revenue and 16-17 pc EBITDA growth for FY 23. Will have to listen to concall to figure out where is such confidence emanating from.
Disc: invested, biased.
Subscribe To Our Free Newsletter |